$AADI
Aadi Bioscience, Inc. Stock $aadi

$aadi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023017234 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$6.202M	$5.867M	$2.307M
YoY Change	80.45%	154.31%	1822.5%
Cost Of Revenue	$656.0K	$529.0K	$179.0K
YoY Change	92.38%	195.53%
Gross Profit	$5.546M	$5.338M	$2.128M
YoY Change	79.13%	150.85%
Gross Profit Margin	89.42%	90.98%	92.24%
Selling, General & Admin	$11.78M	$11.21M	$9.148M
YoY Change	17.69%	22.51%	1524.87%
% of Gross Profit	212.33%	209.95%	429.89%
Research & Development	$13.32M	$10.96M	$6.794M
YoY Change	72.34%	61.26%	86.44%
% of Gross Profit	240.08%	205.25%	319.27%
Depreciation & Amortization	$43.00K	$38.00K	$74.00K
YoY Change	59.26%	-48.65%	3600.0%
% of Gross Profit	0.78%	0.71%	3.48%
Operating Expenses	$25.09M	$22.16M	$15.94M
YoY Change	41.5%	39.02%	184.53%
Operating Profit	-$19.55M	-$16.83M	-$13.81M
YoY Change	6.45%	21.8%	238.0%
Interest Expense	$58.00K	$58.00K	$58.00K
YoY Change	0.0%	0.0%	-74.11%
% of Operating Profit
Other Income/Expense, Net	$1.574M	$1.602M	-$43.00K
YoY Change	1474.0%	-3825.58%	-103.7%
Pretax Income	-$17.97M	-$15.22M	-$13.86M
YoY Change	-1.58%	9.86%	153.05%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$18.00M	-$15.20M	-$13.86M
YoY Change	-1.64%	9.69%	153.05%
Net Earnings / Revenue	-290.23%	-259.08%	-600.65%
Basic Earnings Per Share	-$0.67	-$0.57	-$0.66
Diluted Earnings Per Share	-$0.67	-$0.57	-$662.5K
COMMON SHARES
Basic Shares Outstanding	24.44M shares	24.44M shares	20.91M shares
Diluted Shares Outstanding	26.88M shares	26.86M shares	20.91M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$134.9M	$151.2M	$129.8M
YoY Change	13.6%	16.42%	232.87%
Cash & Equivalents	$68.16M	$34.05M	$129.8M
Short-Term Investments	$66.73M	$117.1M
Other Short-Term Assets	$2.901M	$4.388M	$2.861M
YoY Change	3.31%	53.37%	43.72%
Inventory	$3.457M	$3.803M	$202.0K
Prepaid Expenses
Receivables	$3.676M	$5.565M	$2.708M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$144.9M	$164.9M	$135.6M
YoY Change	16.56%	21.61%	230.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.005M	$2.225M	$619.0K
YoY Change	741.74%	259.45%	335.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.951M	$2.062M	$2.337M
YoY Change	-14.84%	-11.77%	11585.0%
Total Long-Term Assets	$6.305M	$5.724M	$6.699M
YoY Change	46.59%	-14.55%	4032.38%
TOTAL ASSETS
Total Short-Term Assets	$144.9M	$164.9M	$135.6M
Total Long-Term Assets	$6.305M	$5.724M	$6.699M
Total Assets	$151.2M	$170.7M	$142.3M
YoY Change	17.56%	19.91%	245.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.898M	$6.510M	$4.010M
YoY Change	-19.92%	62.34%	774.29%
Accrued Expenses	$9.685M	$10.83M	$7.337M
YoY Change	11.93%	47.65%	339.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.00M	$17.75M	$11.51M
YoY Change	3.18%	54.19%	440.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.813M	$6.921M	$6.181M
YoY Change	6150.46%	11.97%
Total Long-Term Liabilities	$6.813M	$6.921M	$6.181M
YoY Change	6150.46%	11.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.00M	$17.75M	$11.51M
Total Long-Term Liabilities	$6.813M	$6.921M	$6.181M
Total Liabilities	$19.81M	$24.67M	$17.69M
YoY Change	-0.49%	39.44%	730.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$236.4M	-$218.4M	-$156.5M
YoY Change	35.24%	39.55%
Common Stock	$367.9M	$364.4M	$281.2M
YoY Change	29.74%	29.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$131.4M	$146.0M	$124.6M
YoY Change
Total Liabilities & Shareholders Equity	$151.2M	$170.7M	$142.3M
YoY Change	17.56%	19.91%	245.76%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$18.00M	-$15.20M	-$13.86M
YoY Change	-1.64%	9.69%	153.05%
Depreciation, Depletion And Amortization	$43.00K	$38.00K	$74.00K
YoY Change	59.26%	-48.65%	3600.0%
Cash From Operating Activities	-$16.76M	-$21.31M	-$19.42M
YoY Change	56.32%	9.76%	-283.8%
INVESTING ACTIVITIES
Capital Expenditures	$689.0K	$1.369M	$23.00K
YoY Change	-385.89%	5852.17%
Acquisitions
YoY Change
Other Investing Activities	$51.25M	$17.70M
YoY Change
Cash From Investing Activities	$50.56M	$16.33M	-$23.00K
YoY Change	-21079.67%	-71095.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	313.0K	$8.000K	298.0K
YoY Change	-459.77%	-97.32%	324.02%
NET CHANGE
Cash From Operating Activities	-16.76M	-$21.31M	-19.42M
Cash From Investing Activities	50.56M	$16.33M	-23.00K
Cash From Financing Activities	313.0K	$8.000K	298.0K
Net Change In Cash	34.12M	-$4.973M	-19.14M
YoY Change	-408.8%	-74.02%	-281.2%
FREE CASH FLOW
Cash From Operating Activities	-$16.76M	-$21.31M	-$19.42M
Capital Expenditures	$689.0K	$1.369M	$23.00K
Free Cash Flow	-$17.45M	-$22.68M	-$19.44M
YoY Change	66.49%	16.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001422142
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0667
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38560
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AADI BIOSCIENCE, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	61-1547850
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	17383 Sunset Boulevard
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite A250
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39019000	usd
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Pacific Palisades
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90272
CY2023Q1	dei	City Area Code CityAreaCode	424
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	744-8055
CY2023Q1	dei	Security12b Title Security12bTitle	Common stock, $0.0001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	AADI
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24436990	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34046000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	117128000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	133541000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5565000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1862000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	3803000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1861000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4388000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3746000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	164930000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	180029000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2225000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1437000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1522000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2062000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2178000	usd
CY2023Q1	us-gaap	Assets Assets	170654000	usd
CY2022Q4	us-gaap	Assets Assets	184237000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6510000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3519000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10833000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14922000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	404000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	394000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17747000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18835000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1164000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1267000	usd
CY2023Q1	aadi	Due To Licensor DueToLicensor	5757000	usd
CY2022Q4	aadi	Due To Licensor DueToLicensor	5757000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	24668000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	25859000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24436990	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24436990	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24435007	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24435007	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	364437000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	361689000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-115000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-218421000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-203198000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	145986000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	158378000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	170654000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	184237000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5867000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2307000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11207000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9148000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10956000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6794000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	529000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	179000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	22692000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	16121000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16825000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13814000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1660000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	15000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	58000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	58000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1602000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-43000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-15223000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13857000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	83000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15140000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13857000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26862646	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26862646	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20914842	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20914842	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	158378000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2740000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	83000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-15223000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	145986000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	136406000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1781000	usd
CY2022Q1	aadi	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	54000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	244000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13857000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	124628000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-15223000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13857000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2740000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1781000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-1200000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023Q1	aadi	Non Cash Interest Expense NonCashInterestExpense	58000	usd
CY2022Q1	aadi	Non Cash Interest Expense NonCashInterestExpense	58000	usd
CY2023Q1	aadi	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	116000	usd
CY2022Q1	aadi	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	66000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3703000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2708000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1942000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	202000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	642000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	579000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-116000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-125000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-124000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-44000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1544000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4129000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21310000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19415000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1369000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	23052000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	40750000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16329000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	244000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	54000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	298000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4973000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19140000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39083000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148989000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34110000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	129849000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	58000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	58000	usd
CY2023Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2022Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	249000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. In the opinion of management, all adjustments that are considered necessary for fair presentation have been included. The most significant estimates in the Company’s condensed consolidated financial statements relate to fair value of the intangible asset, fair value of the convertible promissory notes, gross-to-net accruals, share-based compensation expense and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	387000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	27000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-218400000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-15200000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13900000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	151200000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39083000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and investments in money market funds, United States government treasury bills, commercial paper, corporate bonds, and government agency debt securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. While the Company has not experienced any losses in such deposits, the recent failure of Silicon Valley Bank, at which the Company holds cash and cash equivalents in multiple accounts, exposed the Company to credit risk prior to the resolution by the Federal Deposit Insurance Corporation in a manner that fully protected all depositors. The Company has not experienced any losses on deposits since inception.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable is derived from customers located in the United States. The Company performs ongoing credit evaluations of its customers and maintains allowances for potential credit losses on customers’ accounts when deemed necessary. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</span></div>
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34046000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39019000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	64000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	64000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34110000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	800000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	100000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2911000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	944000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	892000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	917000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	3803000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1861000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2365000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	609000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	140000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	101000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2225000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508000	usd
CY2023Q1	aadi	Share Based Compensation Arrangement By Share Based Payment Award Stock Plan Offering Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod	P6M
CY2023Q1	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	-32000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	140813000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	46000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	140781000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	165691000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	19000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	134000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	165576000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1299000	usd
CY2023Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1496000	usd
CY2021Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	74200000	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	3900000	usd
CY2023Q1	aadi	Percentage Of Future Net Cash Proceeds Will Be Remitted To Contingent Value Rights Holders PercentageOfFutureNetCashProceedsWillBeRemittedToContingentValueRightsHolders	0.90
CY2023Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P14Y3M18D
CY2023Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3700000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3066000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1814000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2306000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5463000	usd
CY2023Q1	aadi	Accrued Clinical Current AccruedClinicalCurrent	1333000	usd
CY2022Q4	aadi	Accrued Clinical Current AccruedClinicalCurrent	2399000	usd
CY2023Q1	aadi	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	898000	usd
CY2022Q4	aadi	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	405000	usd
CY2023Q1	aadi	Advanced Customer Payments Current AdvancedCustomerPaymentsCurrent	0	usd
CY2022Q4	aadi	Advanced Customer Payments Current AdvancedCustomerPaymentsCurrent	1571000	usd
CY2023Q1	aadi	Accrued Liabilities Other Sales Related Expenses Current AccruedLiabilitiesOtherSalesRelatedExpensesCurrent	1150000	usd
CY2022Q4	aadi	Accrued Liabilities Other Sales Related Expenses Current AccruedLiabilitiesOtherSalesRelatedExpensesCurrent	1435000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	584000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	536000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10833000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14922000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	124000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	28000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1437000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1522000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	404000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	394000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1164000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1267000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1568000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1661000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	116000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	50000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	377000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	512000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	320000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	231000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	280000	usd
CY2023Q1	aadi	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	110000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1830000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	262000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1568000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	404000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1164000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P4Y3M29D
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0748
CY2023Q1	aadi	Royalties Were Accrued On Product Sales RoyaltiesWereAccruedOnProductSales	400000	usd
CY2022Q1	aadi	Royalties Were Accrued On Product Sales RoyaltiesWereAccruedOnProductSales	200000	usd
CY2023Q1	aadi	Right To Terminate License Agreement RightToTerminateLicenseAgreement	P120D
CY2023Q1	aadi	Upfront Payment For License Agreement UpfrontPaymentForLicenseAgreement	14000000	usd
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14000000	usd
CY2021Q1	aadi	Upfront Payment For License Agreement UpfrontPaymentForLicenseAgreement	14000000	usd
CY2023Q1	aadi	Amount Of Certain Development Regulatory And Sales Milestones Payments Eligible To Receive Under License Agreement AmountOfCertainDevelopmentRegulatoryAndSalesMilestonesPaymentsEligibleToReceiveUnderLicenseAgreement	257000000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24436990	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24435007	shares
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2023Q1	aadi	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2990423	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.28
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M2D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2849000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1261506	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.60
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1983	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.45
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	403581	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	20.20
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3846365	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.51
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M23D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1259000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	851373	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.56
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y9M21D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1127000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3846365	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.51
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y8M23D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1259000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.57
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.80
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	16000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2740000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1781000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.57
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.80
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	29167	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	29167	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	40000	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.29
CY2023Q1	aadi	Number Of Class Of Warrants Exercised NumberOfClassOfWarrantsExercised	0	shares
CY2023Q1	aadi	Share Based Compensation Arrangement By Share Based Payment Award Stock Plan Offering Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod	P6M
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	aadi	Accrued Clinical And Contract Manufacturing Expense AccruedClinicalAndContractManufacturingExpense	2200000	usd
CY2022Q4	aadi	Accrued Clinical And Contract Manufacturing Expense AccruedClinicalAndContractManufacturingExpense	2800000	usd
CY2023Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	1500000	usd
CY2023Q1	aadi	Collaboration And Supply Agreement Expense CollaborationAndSupplyAgreementExpense	400000	usd

Files In Submission

Name	View Source	Status
aadi-20230331_def.xml	Edgar Link	unprocessable
0001628280-23-017234-index-headers.html	Edgar Link	pending
0001628280-23-017234-index.html	Edgar Link	pending
0001628280-23-017234.txt	Edgar Link	pending
0001628280-23-017234-xbrl.zip	Edgar Link	pending
aadi-20230331.htm	Edgar Link	pending
aadi-20230331.xsd	Edgar Link	pending
aadi-20230331xex31.htm	Edgar Link	pending
aadi-20230331xex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
aadi-20230331_cal.xml	Edgar Link	unprocessable
aadi-20230331_lab.xml	Edgar Link	unprocessable
aadi-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aadi-20230331_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AADI
Aadi Bioscience, Inc. Stock $aadi

2023 Q2 Form 10-Q Financial Statement

#000162828023017234 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AADI Aadi Bioscience, Inc. Stock $aadi

2023 Q2 Form 10-Q Financial Statement

#000162828023017234 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AADI
Aadi Bioscience, Inc. Stock $aadi